newsfilter
← Latest News
GlobeNewswire·

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

  • Aligos Therapeutics (NASDAQ: ALGS) will report its second quarter 2026 financial results on Thursday, August 6, 2026, before the open of U.S. financial markets.
  • The company is a clinical stage biopharmaceutical firm focused on developing therapies for liver & viral diseases, including chronic hepatitis B virus (HBV) infection.
  • The press release includes forward-looking statements regarding the company's mission & drug development process that are subject to risks & uncertainties.
  • Specific risks include challenges inherent in the clinical stage, clinical trial design, & regulatory approval processes.
  • Detailed risk factors are outlined in the company's Form 10-Q filed with the SEC on May 7, 2026.
  • Aligos states it undertakes no obligation to update forward-looking statements unless required by law.
  • Investor Relations contact is Jordyn Tarazi, Vice President, via phone at (650) 910-0427 or email at jtarazi@Aligos.com.